瑞舒伐他汀钙对冠心病患者外周血内皮前体细胞水平的干预作用

目的 观察瑞舒伐他汀钙片对冠心病患者外周血CD34 与VEGFR-2(血管内皮生长因子-2) 共同标记的血管内皮前体细胞CD34+/VEGFR-2+EPCs 水平的影响,进一步研究他汀类的非调脂作用.方法 选取经皮冠状动脉造影检查明确诊断的冠心病患者112 例,按结果分为单支病变组(37 例)、双支病变组(36 例)、三支病变组(39 例),给予瑞舒伐他汀钙片(10mg1/ 晚) 治疗.治疗前及治疗1 月后,流式细胞仪检测外周血CD34+/VEGFR-2+ EPCs 在全血中所占的比例.结果 1) 瑞舒伐他汀钙片干预1 月后,血浆中总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-CH) 与干预前相比均有显著性下降(P<0.001),甘油三酯(TG) 与干预前相比,呈下降趋势(P<0.05),高密度脂蛋白胆固醇(HDL-C) 变化无统计学意义(P>0.05) ;2) 随着冠脉病变加重,外周血CD34+/VEGFR-2+EPCs 含量逐渐减少(P<0.05) ;3) 在冠状动脉同一病变程度上,冠心病患者外周血中CD34+/VEGFR-2+EPCs 水平较用药前明显上升(P<0.05).结论 他汀类药物除具有较好的调脂作用外,还可以提升外周血中循环内皮前体细胞的数量,有利于减慢冠状动脉粥样硬化进程.

Effect of rosuvastatin on endothelial progenitor cells in peripheral blood of patients with coronary heart disease

Objective To study the lipid-regulating function of rosuvastatin by observing its effect on endothelial prognostic cells(EPC) marked by CD34+ and vascular endothelial growth factor-2+(VEGFR-2+) in peripheral blood of patients with coronary heart disease(CHD).Methods One hundred and twelve patients with CHD diagnosed by percutaneous coronary angiography were divided into single-vessel lesion group(n=37),double-vessel lesion group(n=36) and triple-vessel lesion group(n=39).The patients were treated with 10mg rosuvastatin calcium,once a night.The number of EPC marked with CD34+ and VEGFR-2+ was detected by flow cytometry 1 month before and after treatment.Results The TC and LDL-CH levels were significantly lower 1 month after treatment than before treatment(P<0.001).The TG level was lower after treatment than before treatment(P<0.05),but no significant difference was observed in HDL-CH level(P>0.05).The number of EPC marked with CD34+ and VEGFR-2+ decreased gradually with the aggravation of CHD(P<0.05) and was significantly higher in CHD patients after treatment than before treatment(P<0.05).Conclusion Rosuvastatin can increase the number of EPC in peripheral blood of CHD patients,besides its good lipid-regulating function,thus slowing down the coronary atherosclerotic process.